HealthMore in Health→
Gilead and Merck's Latest Trial Success and Flop: Biotech Roundup
Key Takeaways
- Gilead and Merck had one successful trial and one failed trial.
- AstraZeneca's oral GLP-1 pill showed positive Phase 2b results.
- GSK acquired a cancer startup for $10.6 billion.
- Other news: Regeneron's Eylea, Bluebird Bio gene therapy approval, FDA rejection.
DE
DT Editorial Team··via statnews.com
